UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,137	05/15/2006	Jussi Nurmi	TUR-181	3667
32954 JAMES C. LYI	7590 02/25/201 <b>OON</b>	EXAMINER		
100 DAINGER		MUMMERT, STEPHANIE KANE		
SUITE 100 ALEXANDRIA	A, VA 22314	ART UNIT	PAPER NUMBER	
			1637	
			MAIL DATE	DELIVERY MODE
			02/25/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/579,137	NURMI ET AL.	
Examiner	Art Unit	

	STEPHANIE K. MUMMERT	1637	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 11 February 2011 FAILS TO PLACE THIS A	APPLICATION IN CONDITION FO	R ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	eplies: (1) an amendment, affidavit al (with appeal fee) in compliance	t, or other evidence, whith 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Ac no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth i ter than SIX MONTHS from the mailing	date of the final rejection	on.
Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f Extensions of time may be obtained under 37 CFR 1.136(a). The date chave been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the sleet forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	). on which the petition under 37 CFR 1.13 ension and the corresponding amount o hortened statutory period for reply origin	36(a) and the appropriat of the fee. The appropriat nally set in the final Offic	e extension fee ate extension fee e action; or (2) as
NOTICE OF APPEAL			
<ol> <li>The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exten Notice of Appeal has been filed, any reply must be filed with AMENDMENTS</li> </ol>	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
	out prior to the date of filing a brief	will not be entered be	COLICO
<ol> <li>The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further con (b) They raise the issue of new matter (see NOTE below</li> </ol>	sideration and/or search (see NOT		cause
(c) They are not deemed to place the application in bett appeal; and/or	• •	ducing or simplifying th	ne issues for
(d) They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).	orresponding number of finally reje	cted claims.	
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Cor	mpliant Amendment (	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):			
6. Newly proposed or amended claim(s) would be allownon-allowable claim(s).		imely filed amendmer	nt canceling the
7.  For purposes of appeal, the proposed amendment(s): a) [ how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 18,19 and 21-30. Claim(s) withdrawn from consideration:		be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to over showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after er	ntry is below or attach	ed.
<ol> <li>The request for reconsideration has been considered but <u>See Continuation Sheet.</u></li> </ol>	does NOT place the application in	condition for allowan	ce because:
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	PTO/SB/08) Paper No(s)		
	/Stephanie K. Mummert Primary Examiner, Art U		

Continuation of 11. does NOT place the application in condition for allowance because: Applicant traverses the rejection over Daridon and argues that the "a reference does not anticipate a claim unless (1) the reference discloses all the claim limitations and (2) all of the claim limitations are arranged or combined in the same way as recited in the claim" (p. 2 of remarks). Applicant principally argues that Daridon does not specifically link paragraph 449 with any of paragraph 246, 288 or 307 and argues that these are isolated disclosures of PCR and are improperly combined with the microfluidic particle analysis system and are not directly related to each other (p. 3 of remarks).

These arguments have been considered but are not persuasive. The various paragraphs cited in the rejection necessarily are related to the microfluidic particle analysis of Daridon. The entire framework of the reference is focused on the apparatus for microfluidic particle movement, capture and analysis (see Title, Abstract, claims for a start) and therefore the genetic assays of paragraph 288 and the single cell amplification assay of paragraph 307 necessarily are related to microfluidic particle analysis. Further, the specific embodiment taught in paragraph 449, which discusses retaining particles also specifically requires that the particles are moved to an analysis region for further study. The particular type of analysis was not specified in this paragraph, however it is clear that the particles retained in the device of paragraph 449 are used in downstream applications. The paragraph of 246 in particular notes that amplification or PCR is a type of analysis that is practiced within the microfluidic device. Therefore, contrary to Applicant's argument the claim limitations are all taught and they are arranged in the same manner as claimed and Applicant's arguments are not persuasive. The rejections are maintained.